Abstract
The CD30 antigen, a transmembrane glycoprotein in lymphocytes, is expressed in a spectrum of cutaneous lymphoproliferative disorders (CLPDs), which include lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (PCALCL), and borderline CD30+ lesions. These researchers retrospectively analyzed the records of 56 patients diagnosed with CD30+ CLPDs at Stanford University (31 LyP patients and 25 PCALCL patients). Sixteen LyP patients underwent treatment; most commonly with topical steroids, mechlorethamine …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
